Enhanced dendritic cell-driven proliferation and anti-HIV activity of CD8+ T cells by a new phenothiazine derivative, aminoperazine

Journal of Immunology

Volumn 167, Issue 5, 2001, Pages 2929-2935

  Lu, W ^a   Achour, A ^a   Arlie, M ^a   Cao, L ^a   Andrieu, J M ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPERAZINE; CD8 ANTIGEN; PHENOTHIAZINE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA;

ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLONAL ANERGY; CONTROLLED STUDY; DENDRITIC CELL; DRUG STRUCTURE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOMODULATION; LYMPHOBLASTOID CELL LINE; LYMPHOCYTE CULTURE; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 0035451366     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.5.2929     Document Type: Article

References (35)

1. Immunological abnormalities in the natural history of HIV infection: Mechanisms and clinical relevance
2. Multifactorial nature of human immunodeficiency virus disease: Implications for therapy
3. Viro-immunopathogenesis of HIV disease: Implications for therapy
4. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV-and SIV-infected lymph nodes
5. + T-cell renewal in early HIV-1 infection: Effect of highly active antiretroviral therapy
6. Human immunodeficiency virus type 1 gp120 induces anergy in human peripheral blood lymphocytes by inducing interleukin-10 production
7. + T lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor
8. + T cell anergy
9. Langerhans' cell counts and cervical intraepithelial neoplasia in women with human immunodeficiency virus infection
10. Bone-marrow-derived dendritic cells and the pathogenesis of AIDS
11. Equivalent amplification of intrinsically variable nucleic acid sequences by multiple-primer-induced overlapping amplification assay: Applications for universal detection and quantitation
12. Multi-target PCR analysis by capillary electrophoresis and laser-induced fluorescence
13. + T-cell decrease
14. + cytotoxic T cells
15. Fas ligand (CD95L) and B7 expression on dendritic cells provide counter-regulatory signals for T cell survival and proliferation
16. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART): Swiss HIV Cohort Study
17. + cell counts despite persistently detectable HIV load
18. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study: Swiss HIV Cohort Study
19. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy
20. T-cell recovery in HIV-infected patients experiencing virologic failure under highly active antiretroviral therapy
21. HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: A viral-suppression- independent mechanism
22. + T cells and decreases their susceptibility to apoptosis in vitro and in vivo
23. Early reduction of immune activation in lymphoid tissue following highly active HIV therapy
24. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans
25. Long-term kinetics of T cell production in HIV-infected subjects treated with highly active antiretroviral therapy
26. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine: AIDS Clinical Trials Group
27. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection
28. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
29. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
30. Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients
31. + T cells in individuals receiving highly active antiretroviral therapy (HAART)
32. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy
33. Immunization with soluble protein-pulsed spleen cells induces class I-restricted cytotoxic T lymphocytes that recognize immunodominant epitopic peptides from Plasmodium falciparum and HIV-1
34. Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: Path-way of presentation and regulation by cytokines
35. In vivo cross-presentation of a soluble protein antigen: Kinetics, distribution, and generation of effector CTL recognizing dominant and subdominant epitopes